Business Description
Evofem Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US30048L1044
Description
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.01 | |||||
| Equity-to-Asset | -5.4 | |||||
| Debt-to-Equity | -0.66 | |||||
| Debt-to-EBITDA | -13.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -103.04 | |||||
| Beneish M-Score | 44.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -87 | |||||
| 3-Year EBITDA Growth Rate | 96.6 | |||||
| 3-Year EPS without NRI Growth Rate | 96.2 | |||||
| 3-Year FCF Growth Rate | 97.1 | |||||
| 3-Year Book Growth Rate | 91.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.31 | |||||
| 9-Day RSI | 58.12 | |||||
| 14-Day RSI | 55.95 | |||||
| 3-1 Month Momentum % | -4.79 | |||||
| 6-1 Month Momentum % | -9.6 | |||||
| 12-1 Month Momentum % | -0.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.08 | |||||
| Quick Ratio | 0.05 | |||||
| Days Inventory | 159.27 | |||||
| Days Sales Outstanding | 111.21 | |||||
| Days Payable | 1590.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -992.2 | |||||
| Shareholder Yield % | -227.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 78.83 | |||||
| Operating Margin % | -27.13 | |||||
| Net Margin % | -18.64 | |||||
| EBITDA Margin % | -21.09 | |||||
| FCF Margin % | -20.76 | |||||
| ROA % | -20 | |||||
| ROIC % | -7.26 | |||||
| 3-Year ROIIC % | -255.03 | |||||
| ROC (Joel Greenblatt) % | -460.07 | |||||
| Years of Profitability over Past 10-Year | 1 | |||||
| Moat score | 2 | |||||
| Tariff score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.09 | |||||
| EV-to-EBIT | -10.35 | |||||
| EV-to-EBITDA | -13.31 | |||||
| EV-to-Revenue | 2.81 | |||||
| EV-to-Forward-Revenue | 3.22 | |||||
| EV-to-FCF | -13.51 | |||||
| Earnings Yield (Greenblatt) % | -9.66 | |||||
| FCF Yield % | -304.32 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers